Quick Facts: Levora

• Indicated for contraception
• Aids in the prevention of pregnancy

Levora is a combination of hormones used as an oral contraceptive method. The purpose of this medication is prevention of pregnancy in individuals of reproductive potential who choose to use this type of birth control.

This pharmacological agent functions to modify the regular hormonal cycle to reduce the possibility of conception. Like all contraceptive methods, this drug is one option available for family planning and managing reproductive health.

The intended use and context for administration of this medication are centered on reproductive management.

Regulatory References

1. FDA therapeutic overview for Levonorgestrel and Ethinyl Estradiol

Official Eligibility and Non-Eligibility for Levora

Official regulatory documentation establishes strict rules for who can and cannot use Levora (levonorgestrel/ethinyl estradiol) based on pre-existing health conditions and specific risk factors, primarily related to the potential for serious cardiovascular events.

---

Populations for Whom Use is Forbidden (Contraindications)

Levora is contraindicated and must not be used by individuals with the following high-risk conditions, as stated in the label:

• Smoking and Age: Females over age 35 who smoke.
• Vascular Disease: Current or history of deep vein thrombosis, pulmonary embolism, stroke, coronary artery disease, or inherited/acquired blood clotting disorders.
• Cardiovascular Conditions: Uncontrolled hypertension or hypertension with vascular disease, or certain thrombogenic heart valve conditions.
• Specific Conditions: Current or history of breast cancer (which may be hormone-sensitive), liver tumors, severe cirrhosis, acute viral hepatitis, or undiagnosed abnormal uterine bleeding.

Eligibility Status by Physiological State

State	Official Eligibility Status
Pregnancy	Contraindicated (Must discontinue if pregnancy is suspected)
Lactation	Not Recommended (May decrease milk production)
Postpartum	Must wait at least 4 weeks after delivery (if not breastfeeding)

Age-Related Eligibility and Restrictions

Levora is indicated for use by females of reproductive potential. Its use is not indicated before menarche (the onset of menstruation). Use in females requires a consideration of cardiovascular risk factors, particularly for those over 35 years of age. Additionally, the drug must be stopped 4 weeks before and through 2 weeks after major surgery due to the risk of blood clots.

The documented interaction profile for Levora (Ethinyl Estradiol/Levonorgestrel) is defined by pharmacokinetic patterns that alter the concentration of the active hormones, as stated in regulatory labels.

One formal, interaction-related constraint is the contraindication with specific combination medications used to treat Hepatitis C, including those containing Ombitasvir, Paritaprevir, and Ritonavir (with or without Dasabuvir). This prohibition is mandatory due to the officially documented potential for elevations in liver enzymes (ALT).

Many clinically significant interactions involve enzyme-mediated exposure changes. Co-administration with enzyme-inducing substances, such as certain antiepileptic medicines (e.g., Phenytoin, Carbamazepine), the antibiotic Rifampicin, and the herbal product St John's wort, increases the metabolic clearance of the hormones. This reduction in systemic plasma exposure may decrease contraceptive effectiveness. Conversely, some substances, categorized as CYP enzyme inhibitors (e.g., certain Azole antifungals), are documented to slow the hormone clearance, leading to an increase in their systemic plasma concentrations.

Interaction-related conditions also involve administration timing. The official labeling notes that if severe vomiting or diarrhea occurs within three to four hours after taking a tablet, hormone absorption may be compromised, requiring management for a missed dose.

Central Neuroendocrine Cycle Suppression

Levora's mechanism is driven by its synthetic hormones, Ethinyl Estradiol and Levonorgestrel, which act as agonists at the Estrogen and Progesterone Receptors ( ER/ PR) in the hypothalamus and pituitary. This receptor activation imposes potent negative feedback on the Hypothalamic-Pituitary-Ovarian (HPO) Axis, suppressing the release of FSH and the mid-cycle LH surge. The resulting physiological effect is anovulation, characterized by the cessation of the normal follicular rupture and ovum release.

Peripheral Tissue Modulation

Levonorgestrel exerts direct, peripheral action on reproductive tract tissues. It acts on Progesterone Receptors in the cervix to increase the viscosity and density of the cervical mucus, forming a physiological barrier that interferes with sperm motility and penetration. Furthermore, the combination alters the endometrial tissue state by inhibiting normal proliferation, establishing a non-proliferative, early secretory state.

Layered Mechanism Synergy

This multi-layered approach leverages synergy, where Levonorgestrel performs the main anti-ovulatory block, and Ethinyl Estradiol reinforces follicular suppression. The core physiological changes establish a multi-layered state characterized by anovulation, high cervical mucus viscosity, and altered endometrial morphology.

How to Use Levora (Levonorgestrel and Ethinyl Estradiol Tablets)

Instructions for using Levora establish a daily, continuous 28-day cycle of oral administration, strictly defined by the order of tablets in the dispenser. The medication must be taken orally, one tablet at the same time each day, regardless of meals.

---

Administration and Scheduling

The 28-day regimen consists of 21 consecutive days of white (active) tablets followed by 7 consecutive days of peach (inactive) tablets.

Procedural Step	Instruction
Starting the Pack	Begin on either the first day of menses (Day 1 Start) or the first Sunday after menses begins (Sunday Start).
Dosing	Take one tablet daily, following the numbered sequence in the pack.
New Cycles	Start a new pack immediately after the last tablet of the previous pack is finished, ensuring no gap days.

Management of Missed Doses

Missed active tablets require specific, immediate action based on the number of tablets missed and the week of the cycle. For instance, if one active tablet is missed, it should be taken as soon as it is remembered, even if this means taking two tablets on the same day. Missing two or more active tablets may require specific steps, such as discarding part of the pack and starting a new pack, and requires the use of an additional non-hormonal contraceptive method for 7 days.

Population-Specific Use

For non-lactating postpartum women, administration should not begin until 4 weeks after delivery. Use is generally not recommended for breastfeeding women.

Research evidence / Overview of studies for Levora

Evidence for Use in Preventing Pregnancy (Contraception)

The primary research on combined hormonal contraceptives, including the combination found in Levora (Ethinyl Estradiol and Levonorgestrel), centers on its intended regulatory-approved use. Studies for this purpose are primarily large-scale Randomized Controlled Trials (RCTs) and prospective observational studies.

These research efforts examined how researchers measured outcomes related to preventing conception in healthy women of reproductive age. The main metric used was the Pearl Index, which is a measurement of how many unintended pregnancies were observed for every 100 women using the method over one year. Clinical trials reported measurements of the Pearl Index, a failure rate metric, in the 'per-protocol' study populations (those with perfect adherence). Observational studies focused on 'typical use' settings, where findings suggest failure rates were higher, accounting for variations in adherence.

---

Evidence on Menstrual Cycle Patterns

Research explored how the medication was observed in studies to affect the menstrual cycle. This was generally examined as a secondary outcome within the larger contraceptive trials. These studies monitored outcomes related to systemic or functional imbalance by tracking the frequency and duration of bleeding and spotting.

The research describes patterns where studies monitored measurements of cycle regularity. Trials documented variations in the reported incidence of unscheduled bleeding and spotting, generally showing that the incidence of unscheduled bleeding and spotting appeared to stabilize over subsequent cycles.

---

What Remains Uncertain About Levora Research

While extensive research exists, long-term outcomes are not fully established with controlled research; the data are largely derived from post-marketing surveillance and observational studies. The difference between 'perfect use' (in trials) and 'typical use' (real-world adherence) remains a major limitation, meaning that findings describe group patterns, not personal outcomes or individual prediction of success. Research does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

Key Studies & References

1. Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.15 mg/0.03 mg - DailyMed (NIH)
2. Pearl Index: A measure to assess the efficacy of contraceptive methods (general methodology)

Common questions about Levora (FAQ)

Q: What happens if I miss a Levora pill?

A: Official guidance exists for managing missed active pills. Management protocols may involve specific actions such as taking a pill as soon as remembered, potentially taking two in one day, or using a backup non-hormonal method, depending on how many pills were missed and the timing in the cycle.

Q: Does taking Levora increase the risk of blood clots?

A: Official warnings caution that the use of oral contraceptives is associated with an increased risk of serious conditions, including blood clots (thromboembolism). This risk is highest during the first year of initial use or when restarting the medication after a break of four weeks or more.

Q: Can Levora be taken by women over 35?

A: Official product information states that Levora is strictly contraindicated (must not be used) in women over age 35 who smoke. For women over 35 who do not smoke, use requires consideration of specific cardiovascular risk factors, as noted in the label.

Q: How soon after giving birth can someone safely start Levora?

A: For women who are not breastfeeding, regulatory documents advise waiting at least four weeks after delivery before starting Levora due to the elevated risk of blood clots during this period. Regulatory documents caution against use in women who are currently breastfeeding, as it may decrease milk production.

Q: Will I have a period if I take the active Levora pills continuously?

A: Levora is designed for a 28-day cycle that includes seven inactive pills, which typically results in a withdrawal bleed. If the inactive tablets are skipped and only the active tablets are taken continuously, it may result in irregular bleeding or spotting.

Q: Why is it important to take Levora at the same time every day?

A: Regulatory instructions require taking one tablet at the same time each day. This consistency is critical for maintaining effective and steady levels of the hormones in the bloodstream, which is necessary to prevent pregnancy.

Q: Is Levora the same type of birth control as other pills?

A: Levora is a Combination Hormonal Contraceptive (CHC), containing both synthetic estrogen and progestin. It is classified as a monophasic pill, meaning the active hormone doses remain fixed throughout the 21 active days of the cycle.

Q: How quickly after starting Levora is it effective as birth control?

A: The time until effectiveness varies depending on the initiation method. If the pill is started on Day 1 of the menstrual cycle, the label indicates that contraceptive protection begins immediately. If started on the Sunday following your period, a backup method is required for the first 7 days.

Q: Is it normal to have spotting or breakthrough bleeding when starting Levora?

A: Yes, irregular vaginal bleeding or spotting between periods is officially documented as a common side effect. This is most likely to occur during the first three months of starting the pill and often stabilizes over time.

Q: Does Levora cause weight gain in most people?

A: Changes in weight, including both increases and decreases, have been officially reported as an adverse reaction. However, clinical trial data does not classify weight changes as a very common side effect.

Q: Can Levora affect my mood or cause depression?

A: Depression and mental depression are listed in regulatory documents as officially documented adverse reactions. Women with a history of depression should be monitored carefully while using this type of medication.

Q: Are headaches a common side effect of taking Levora?

A: Headache is officially documented as a very common adverse reaction, meaning it was reported in 10% or more of users in clinical studies.

Q: Can Levora help with acne or skin issues?

A: Acne is officially documented as a common adverse reaction in regulatory documents. However, Levora is only officially indicated for the prevention of pregnancy.

Q: When should I expect my period while taking Levora?

A: The withdrawal bleed, which is similar to a period, typically begins during the 7 consecutive days when the peach (inactive) tablets are taken in the 28-day cycle.

Q: Does Levora affect fertility after I stop taking it?

A: The contraceptive effect of Levora is temporary. After stopping the pill, a return to pre-treatment fertility is generally expected, though the specific timeline can vary among individuals.

Q: Is there a generic version of Levora available?

A: Yes, Levora is a brand-name product. Regulatory and market data confirm that there are several generic versions of the same levonorgestrel/ethinyl estradiol combination available.

Q: How long does Levora stay in your system after stopping?

A: The synthetic hormones in Levora have short half-lives. Based on this pharmacological data, the medication is generally cleared from the body within a few days after the last active pill is taken.

Q: Can Levora change the flow or duration of my menstrual period?

A: Changes in menstrual flow are officially documented. Many users of combination oral contraceptives may notice a decrease in blood loss and a shorter duration of their withdrawal bleed.

Q: Is it common to feel nauseous when first starting Levora?

A: Nausea is officially documented as a very common adverse reaction, meaning it was reported in 10% or more of users in clinical studies.

Q: Does grapefruit juice interact with Levora?

A: The hormones in Levora are processed by specific liver enzymes (CYP3A4). While grapefruit juice is not explicitly named in the official label, it is a known inhibitor of these enzymes and may potentially affect the level of the hormone in the bloodstream.

Q: What types of over-the-counter medications might interact with Levora?

A: Regulatory documents state that certain over-the-counter products, such as the herbal supplement St. John's wort, can interact with Levora. This type of interaction may potentially reduce the pill's contraceptive effectiveness.

Q: Does Levora affect the results of any common lab tests?

A: Yes, official precautions note that combination oral contraceptives can affect the results of certain endocrine and liver function tests. They may also cause changes in some blood components.

Q: Can smoking affect how well Levora works or increase risks?

A: Official warnings explicitly state that smoking substantially increases the risk of serious cardiovascular events, such as blood clots and stroke. This is especially true for women over 35 who use oral contraceptives.

Q: Is it true that Levora can help reduce the risk of certain cancers?

A: While Levora is only indicated for pregnancy prevention, studies involving combination oral contraceptives (COCs) have suggested a reduced lifetime risk of ovarian and endometrial cancers.

Q: What if I vomit shortly after taking a Levora pill?

A: Official labeling advises that if severe vomiting or diarrhea occurs within three to four hours after taking an active tablet, the absorption of the hormones may be compromised. In this situation, the necessary steps for management should be followed, as hormone absorption may be compromised.

Q: Does Levora affect libido or sexual desire?

A: Changes in sexual desire, including reports of both increased and decreased interest, have been listed as documented adverse reactions reported by users.

Q: Does Levora affect cholesterol levels?

A: Official warnings state that oral contraceptives may cause changes in the levels of fats (lipids) in your blood. The use of certain progestogens may also affect lipid profiles, including potentially elevating LDL cholesterol levels.

Q: What's the difference in hormones between Levora and a progestin-only pill?

A: Levora is a combination pill containing both an estrogen (ethinyl estradiol) and a progestin (levonorgestrel). A progestin-only pill (sometimes called the mini-pill) contains only a progestin hormone.

Q: Is it normal to have tender breasts on Levora?

A: Breast tenderness or pain is officially documented as a common adverse reaction, reported in 1% to 10% of users in clinical studies.

Q: Does taking Levora affect the frequency of migraines?

A: New or worsening headaches, including migraine headaches, are listed as officially documented adverse reactions. The presence of migraines with aura is a specific contraindication for using this medication.

Q: Do you need a specific type of follow-up while on Levora?

A: Regulatory guidance suggests that it is considered good medical practice for all women using oral contraceptives to have annual history and physical examinations. This follow-up may include checking blood pressure and relevant laboratory tests.

Storage and Disposal of Levora

Official labeling mandates specific conditions for storing Levora (levonorgestrel and ethinyl estradiol tablets) to preserve the product's integrity.

Item	Regulatory Requirement
Temperature	Store at Controlled Room Temperature (20°C to 25°C or 68°F to 77°F).
Protection	Protect from light and moisture and store in a closed container.
Container Rule	Do not use if the blister seal is broken or missing.
Child Safety	Keep out of the reach of children.
Disposal	Ask a healthcare professional how to dispose of any medicine that is no longer needed.

These requirements strictly define the environment for Levora, demanding storage within the specified temperature range and demanding protection from environmental factors like light and moisture. The official labeling also requires that the medicine be kept away from children, and specifies that disposal of unused product must follow the guidance of a healthcare professional.